- FoI Number
- 2024-300
- Subject
- Biologic and Biosimilar Products
- Date Received
- 06/09/2024
- Request and Response
-
- Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:
Medication
No. patients
Abatacept [Orencia]
<5
Adalimumab [Humira]
<5
Adalimumab Biosimilars
34
Apremilast [Otezla]
0
Baricitinib [Olumiant]
0
Bimekizumab [Bimzelx]
0
Certolizumab [Cimzia]
<5
Etanercept [Enbrel]
<5
Etanercept Biosimilars
17
Filgotinib [Jyseleca]
0
Golimumab [Simponi]
<5
Guselkumab [Tremfya]
0
Infliximab [Remicade]
0
Infliximab Biosimilars
5
Ixekizumab [Taltz]
0
Risankizumab [Skyrizi]
0
Rituximab [MabThera]
0
Rituximab Biosimilars
<5
Sarilumab [Kevzara]
0
Secukinumab [Cosentyx]
6
Tocilizumab [Ro Actemra]
<5
Tocilizumab Biosimilars
<5
Tofacitinib [Xeljanz]
<5
Upadacitinib [Rinvoq]
0
Ustekinumab [Stelara]
0
Ustekinumab Biosimilar
0
Where we have given <5 answers this is because NHS Shetland considers that providing more specific information carries a high risk of identifying individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.
